(Q28291395)

English

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

scientific article

In more languages

Statements

scholarly article

0 references

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) (English)

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andreas Schneeweiss

1

object named as

A Schneeweiss

0 references

author name string

S Chia

2

0 references

T Hickish

3

0 references

V Harvey

4

0 references

A Eniu

5

0 references

R Hegg

6

0 references

C Tausch

7

0 references

J H Seo

8

0 references

Y-F Tsai

9

0 references

J Ratnayake

10

0 references

V McNally

11

0 references

G Ross

12

0 references

J Cortés

13

0 references

language of work or name

0 references

publication date

September 2013

0 references

Annals of Oncology

0 references

24

0 references

2278-84

0 references

9

0 references

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT182

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28291395&oldid=1966918857"